Objectives: Resistance to carbapenems in Aeromonas species is rare and mediated mostly by the chromosomal cphA gene. Our aims were to describe the molecular characteristics of the first cases of VIM-producing Aeromonas caviae isolated from human samples.
Introduction
Aeromonads are ubiquitous in the microbial biosphere and can be isolated from every environmental niche, including aquatic habitats, food, vertebrate and invertebrate species and natural soils. 1 Consequently, humans may be constantly exposed to aeromonads and may acquire them from a variety of sources. Although the genus Aeromonas includes .20 different species, 1 3 species (Aeromonas hydrophila, Aeromonas caviae and Aeromonas veronii bv. sobria) account for the vast majority of human infections and clinical isolates. 2 Aeromonads may cause a variety of clinical infections in both immunocompetent and immunocompromised individuals, typically including gastroenteritis, soft tissue infection and bacteraemia. Aeromonas spp. may produce different types of broadspectrum b-lactamases, including AmpC and extended-spectrum b-lactamase (ESBL)-type enzymes. In addition, Aeromonas spp. may harbour a unique inducible metallo-b-lactamase (MBL) gene, designated cphA, that can be found in the majority of A. hydrophila isolates. 3 Although commonly referred to as a carbapenemase, actual in vitro resistance to carbapenems is seen in only a minority of cphA-induced isolates. 4 As bla CphA is located on the chromosome and is found in this genus alone, its clinical significance is probably limited, as is concern for its likely dissemination. 4 In contrast, the MBL VIM confers resistance to all b-lactam antimicrobials (with the exception of aztreonam) and has been identified across the world in a wide variety of species, 5 thereby representing one of the greatest problems in the realm of antimicrobial resistance. To date, only a single case of a VIM-producing aeromonad, A. hydrophila, has been reported. 6 In this study, we report the first cluster of VIM-producing A. caviae, identified in five patients in two medical centres in Israel, and describe their microbiological and molecular characteristics. a population of 400000 people. Carbapenem-resistant bacteria are routinely sent from these hospitals to the National Center for Infection Control laboratory for molecular characterization. Surveillance rectal cultures were inoculated in both centres onto CHROMagar KPC medium (HyLabs, Rehovot, Israel) and pigmented colonies were further tested for species identification and antimicrobial susceptibility testing (LH, Vitek 2 system; SZMC, manual biochemical tests and disc diffusion). Phenotypic characterization included the modified Hodge test (MHT), ertapenem-EDTA synergy testing 7 and the Carba NP imipenem hydrolysis assay. 8 
Methods

Set-up and microbiological methods
Molecular methods
PCR for bla NDM , bla VIM , bla IMP , bla CTX-M, bla SHV and bla TEM were performed as previously described. 9 -11 Sequencing of the entire bla VIM gene was done as previously described. 12 PCR for the chromosomal bla CphA gene was done using the following primers: cphA 4-F, 5
′ -CATGGTCTATTTCGGGGCCA-3 ′ ; and cphA 603-R, 5
′ -GCCTTGATCAGCTCTTCGTAGTGATC-3 ′ . Previously identified bla CphA -containing isolates were used as controls.
Sequence-based identification of Aeromonas spp. was done using dnaJ sequencing. 13 The clonal structure was studied by PFGE following SpeI digestion. 14 The variable region of the class I integron was amplified as previously described 15 and the entire amplicon was sequenced. Plasmid DNA was purified from the five isolates using the QIAGEN Plasmid Midi Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Transformation into Escherichia coli DH10B was attempted using electroporation, with Lysogeny broth (LB) agar supplemented with either 100 mg/L ampicillin or 10 mg/L cefazolin as selection medium. A chromosomal versus plasmid location of the bla VIM gene was studied using Southern blotting of the I-CeuI-digested genome 16 with 16S rRNA and bla VIM probes.
Results and discussion
Carbapenem-resistant Aeromonas (CRA) spp. isolates were detected in rectal surveillance cultures as hazy blue colonies on CHROMagar KPC medium. The isolation date and institution for each isolate are listed in Table 1 . Contact precautions were implemented for all CRA carriers. Clinical infections due to CRA were not identified in any of these patients or in any other patient in these institutions. Isolates were first identified as Aeromonas spp. at the local laboratories and were later identified as A. caviae by dnaJ sequencing.
13 Carbapenem MICs ranged from 0.5 -8 mg/L for ertapenem and imipenem and 0.25 -8 mg/L for meropenem (Table 1 ). All isolates were resistant to the b-lactams ceftriaxone, ceftazidime and piperacillin/tazobactam, as well as to gentamicin and trimethoprim/sulfamethoxazole; all were susceptible to amikacin and ciprofloxacin (except one). All were positive by the MHT and the Carba NP test and all but one (isolate 669) showed synergy between ertapenem and EDTA.
All isolates yielded positive results on PCR testing for bla VIM , carrying either bla VIM-1 or a single nucleotide variant, bla VIM-35 . PCR tests for other metallo-carbapenemase genes, including bla NDM , bla IMP and bla CphA , were negative. All isolates produced bla TEM-1 and tested negative for the presence of ESBL genes. Comparison of the SpeI macrorestriction patterns revealed a heterogeneous population, with only two isolates showing similarity (81 and 1254, data not shown). The bla VIM gene was located inside a class I integron, with two different sizes to its variable region (Table 1 and Figure 1 ). The 4650 bp integron included an ISPa21-type transposase gene and was almost identical to a bla VIM -harbouring integron that was identified in Enterobacter cloacae isolated in the United Arab Emirates. 17 This integron was also identical to the 3300 bp integron except for a missing 1350 bp fragment in the latter. The bla VIM gene was not transferable by electroporation using a DH10B E. coli recipient strain. In one isolate (1045), a few bla VIM PCR-positive transconjugant colonies were identified. However, Southern blotting of the I-CeuI-digested genome the 1045 isolate showed a chromosomal location of the gene (data not shown) and the transconjugant strains were completely susceptible to carbapenems. Also, no bla VIM -harbouring plasmid was extracted from the recipient strain, despite multiple attempts. Antimicrobial susceptibility testing was performed using the Vitek 2 system. c Size of the variable region of the bla VIM -harbouring class I integron.
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This study represents the first reported cluster of VIM-producing A. caviae, with five cases detected in two medical centres, and the first report of VIM-producing bacteria in Israel. Two of the isolates (8 and 669) were fully susceptible to carbapenems and only one (isolate 81) was resistant to imipenem and meropenem. Although these findings differ from the previous report of VIM in Aeromonas, which involved A. hydrophila, 6 relatively low MIC values have also been reported in VIM-producing Klebsiella pneumoniae isolates. 18 Similar to previous reports of MBL-producing Aeromonas spp., 4, 6 these isolates tested positive by the MHT and the ertapenem -EDTA synergy test (except for isolate 669).
As previously described in both Aeromonas and other Gram-negative organisms, 6, 17, 18 the bla VIM gene was located inside two variants of a class I integron. Both types also harboured additional antimicrobial resistance (AMR) genes and a transposase gene indicative of its plasticity as well as its transmissibility potential. Only two isolates had similar PFGE patterns, but they differed in their bla VIM allele. This heterogeneity in molecular features indicates that both clonal spread and horizontal gene transfer play a role in the dissemination of this resistance mechanism. The connection between these patient carriers remains elusive, probably since these findings were incidental and hence targeted screening for other carriers was not performed.
All of the isolates in this study were recovered from rectal culture only, as an incidental finding of the carbapenem-resistant Enterobacteriaceae surveillance programmes implemented in these centres in the context of a national infection control intervention. 19 Although foodborne outbreaks of Aeromonas gastroenteritis have been reported, 1 there are almost no data regarding the transmission of this organism in the hospital environment. In 1987, Sherlock et al. 20 reported a high proportion (8%) of intestinal colonization by A. hydrophila in patients with haematological malignancies. Although molecular typing was not done in this study, it highlights the possibility of nosocomial transmission of Aeromonas spp. by colonized patients, similar to patterns seen with other enteric organisms, such as enterococci and Enterobacteriaceae. Also, Aeromonas spp. can potentially spread via the water or sewage systems within the hospital or out to the community. Although clinical infections due to Aeromonas spp. are relatively uncommon, the dissemination of VIM-producing Aeromonas spp. is worrisome due to the potential for horizontal transmission of this gene to more clinically important pathogens, e.g. K. pneumoniae. As with other AMR Gram-negative organisms, strict adherence to infection control practices and meticulous environmental cleaning are likely to have some benefit in controlling spread. Whether these measures will suffice or additional, organism-specific measures will be required has yet to be determined.
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